"Antibody Affinity" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes.
| Descriptor ID |
D000915
|
| MeSH Number(s) |
G12.040 G12.122.125
|
| Concept/Terms |
Antibody Affinity- Antibody Affinity
- Affinity, Antibody
- Affinities, Antibody
- Antibody Affinities
Antibody Avidity- Antibody Avidity
- Antibody Avidities
- Avidities, Antibody
- Avidity, Antibody
|
Below are MeSH descriptors whose meaning is more general than "Antibody Affinity".
Below are MeSH descriptors whose meaning is more specific than "Antibody Affinity".
This graph shows the total number of publications written about "Antibody Affinity" by people in this website by year, and whether "Antibody Affinity" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 2004 | 1 | 2 | 3 |
| 2009 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibody Affinity" by people in Profiles.
-
Domeier PP, Chodisetti SB, Schell SL, Kawasawa YI, Fasnacht MJ, Soni C, Rahman ZSM. B-Cell-Intrinsic Type 1 Interferon Signaling Is Crucial for Loss of Tolerance and the Development of Autoreactive B Cells. Cell Rep. 2018 07 10; 24(2):406-418.
-
Lewin ER, Dasgupta A, Valdes R, Stickle DF. Model analysis of bidirectional interference in two-stage labeled-ligand immunoassays. Clin Biochem. 2017 Dec; 50(18):1188-1197.
-
Donaldson JM, Kari C, Fragoso RC, Rodeck U, Williams JC. Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies. Cancer Biol Ther. 2009 Nov; 8(22):2147-52.
-
Cenna J, Hunter M, Tan GS, Papaneri AB, Ribka EP, Schnell MJ, Marx PA, McGettigan JP. Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates. J Infect Dis. 2009 Oct 15; 200(8):1251-60.
-
Colby DW, Chu Y, Cassady JP, Duennwald M, Zazulak H, Webster JM, Messer A, Lindquist S, Ingram VM, Wittrup KD. Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc Natl Acad Sci U S A. 2004 Dec 21; 101(51):17616-21.
-
Dimitrijevic LA, Stojanovic M, Ciric B, Radulovic M, Stojanovic R, Popovic Z, Inic-Kanada A, Zivkovic I. Expression of Y7 cross-reactive idiotope on human IgM molecules. Immunol Invest. 2004 Feb; 33(1):1-14.
-
Colby DW, Kellogg BA, Graff CP, Yeung YA, Swers JS, Wittrup KD. Engineering antibody affinity by yeast surface display. Methods Enzymol. 2004; 388:348-58.
-
Nair J, Fair JH, Burdick JF, Stephenson GR, Klein AS, Olson JL, Maley WR, Kittur DS. Role of naturally occurring xenoantibodies in hyperacute rejection strengthened by their avid binding to ex vivo pig to human liver xenografts and to isolated pig liver preparations. Transplant Proc. 1994 Jun; 26(3):1344-5.